PolarCool (POLAR) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 reached 0.6 MSEK, up 69% year-over-year, with full-year sales at 2.1 MSEK, a 51% increase, driven by expanded contracts in European sports leagues.

• Strategic recruitment of a European sales chief and intensified marketing aim to accelerate growth and scale-up.

• Market approvals in Australia and South Africa, and progress toward US FDA approval, open new global opportunities.

Financial highlights

• Q4 net sales: 577 TSEK (341 TSEK Q4 2023); full-year: 2,083 TSEK (1,373 TSEK 2023).

• Operating loss for Q4: -2,938 TSEK (Q4 2023: -2,336 TSEK); full-year net loss: -11,025 TSEK (2023: -12,106 TSEK).

• Cash and cash equivalents at year-end: 7,380 TSEK (1,632 TSEK prior year).

• Equity at year-end: 12,468 TSEK; equity ratio: 82% (46% prior year).

Outlook and guidance

• Focus on scaling up in Europe to achieve profitability in 2025, with cost control and increased sales as priorities.

• US market launch targeted for late 2025, pending FDA approval.

• Ongoing clinical and health economic studies to support product adoption and market expansion.